Noam Pilpel

Noam has been leading R&D teams for over a decade in both academic and industrial settings. She specializes in the fields of cell biology in the context of cancer and the biology of aging - searching for new medicines for "old" conditions. Noam graduated her Ph.D. summa cum laude from the Max Planck Institute for Medical Research in Heidelberg, Germany, studying molecular neuroscience.​

She performed two post-doctoral studies at the Sanford-Burnham Institute in San Diego, studying cell death pathways in cancer, and at the Weizmann Institute of Science studying the molecular mechanisms of aging. Her innovative research yielded both patents and publications in high-impact scientific journals such as Nature Communications and others.

Noam led projects and teams from early stage development to pre-clinical studies.

Prior to joining Gilboa Therapeutics, she worked at BiolineRx as an oncology Drug Development Manager, at Targetgene Biotechnologies as Gene Therapy Lead, and at Augmanity Nano as an R&D Director. In these companies, she was part of senior management and led fundraising activities.